4,040 Shares in Edwards Lifesciences Co. (NYSE:EW) Bought by Accent Capital Management LLC

Accent Capital Management LLC purchased a new position in Edwards Lifesciences Co. (NYSE:EWFree Report) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 4,040 shares of the medical research company’s stock, valued at approximately $308,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Norges Bank purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth $648,540,000. Brown Advisory Inc. lifted its holdings in shares of Edwards Lifesciences by 20.1% during the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock valued at $1,386,333,000 after purchasing an additional 3,048,274 shares in the last quarter. CIBC Private Wealth Group LLC lifted its holdings in shares of Edwards Lifesciences by 197.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company’s stock valued at $262,815,000 after purchasing an additional 2,286,119 shares in the last quarter. AustralianSuper Pty Ltd bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $168,519,000. Finally, Sands Capital Management LLC lifted its holdings in shares of Edwards Lifesciences by 34.6% during the fourth quarter. Sands Capital Management LLC now owns 6,103,702 shares of the medical research company’s stock valued at $465,407,000 after purchasing an additional 1,567,526 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded down $0.42 during trading on Monday, hitting $86.87. The company had a trading volume of 2,093,527 shares, compared to its average volume of 3,387,409. The stock has a 50 day simple moving average of $87.65 and a 200 day simple moving average of $84.07. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The firm has a market capitalization of $52.35 billion, a P/E ratio of 37.44, a price-to-earnings-growth ratio of 3.19 and a beta of 1.11.

Edwards Lifesciences (NYSE:EWGet Free Report) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. As a group, analysts anticipate that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total transaction of $437,700.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $4,108,777.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total value of $437,700.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $4,108,777.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Bernard J. Zovighian acquired 580 shares of Edwards Lifesciences stock in a transaction on Monday, May 6th. The stock was purchased at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the purchase, the chief executive officer now owns 3,268 shares in the company, valued at $280,198.32. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 127,104 shares of company stock worth $11,267,464. 1.27% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Wells Fargo & Company upped their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a report on Friday, April 26th. Barclays upped their price target on Edwards Lifesciences from $100.00 to $101.00 and gave the company an “overweight” rating in a report on Tuesday, May 7th. StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Evercore ISI lowered their price target on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a report on Friday, April 26th. Finally, OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $95.06.

Get Our Latest Stock Report on EW

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Read More

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.